Find Funding Opportunities

The purpose of this Notice of Special Interest (NOSI) is to promote the availability of Mentored Clinician Scientist Research Career Development Awards (K08) applications in research areas covered by the NIH BRAIN Initiative. This program will provide support and protected time (3-5 years) for clinicians to develop new and/or expand their expertise in intracranial human neuroscience research. The goal of the program is to build an interdisciplinary and diverse research workforce dedicated to capitalizing on intracranial neural recording and/or stimulating technologies to answer high-impact questions in human neuroscience.

This Notice of Funding Opportunity (NOFO) invites applications for basic, translational, and clinical research projects that propose to study the role of environmental stress on the health inequities in Alzheimer’s Disease Related Dementias (ADRD), including Frontotemporal Dementia (FTD), Lewy Body Dementia (LBD), Vascular Contributions to Cognitive Impairment and Dementia (VCID), and Mixed-Etiology Dementia (MED). Environmental stressors include but are not limited to heat, crowding, air pollution, noise, violence, and psychosocial stress. Many of these environmental stressors are more prevalent in rural and urban disadvantaged communities which also have a higher risk for ADRD. Thus, there is a need to identify environmental stressors that impact health inequities in ADRD and to determine the mechanistic underpinnings of this stress. This NOFO will support mechanistic, translational, and human subject studies to understand the relationship between environmental stressors and health inequities in ADRD. It is expected that these studies will identify environmental stressors related to health inequities in ADRD and their clinical relevance. Ultimately, these studies should accelerate research towards better therapeutic interventions and quality of life.

The purpose of this notice is to extend PAR-20-185 "NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)" by one additional council round.

The purpose of this Notice of Funding Opportunity (NOFO) is to support the NeuroImaging Tools and Resources Collaboratory and to enable collaborative research in neuroimaging informatics. The competition is limited to the U24 awardees and subawardees of RFA-EB-16-002.

This Notice of Funding Opportunity (NOFO), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small businesses to submit Small Business Innovation Research (SBIR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH, CDC, and FDA awarding components identified in this NOFO are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2022-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA. This Parent Funding Opportunity Announcement does not accept clinical trials.

This Notice of Funding Opportunity Announcement (NOFO), issued by the National Institutes of Health (NIH) invites eligible United States small businesses to submit Small Business Technology Transfer (STTR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH awarding components identified in this NOFO are encouraged to submit STTR grant applications in response to identified topics (see PHS 2022-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA). This Parent Funding Opportunity Announcement does not accept clinical trials.

Changing the first receipt date from 9/6/23 to 11/15/23.

The purpose of this Notice of Funding Opportunity (NOFO) is to support the NeuroImaging Tools and Resources Collaboratory and to enable collaborative research in neuroimaging informatics. The competition is limited to the U24 awardees and subawardees of RFA-EB-16-002.

This Notice of Funding Opportunity (NOFO) supports the optimization of promising genome editing-based therapeutic leads for Alzheimer's Disease-Related Dementias (ADRD), towards IND-enabling studies. Specifically, it supports the characterization and optimization of therapeutic lead(s) that show promise as potential genome editing therapeutics, as evidenced by convincing proof-of-concept studies in appropriate models. At the end of the funding period, successful projects will have optimized a genome editing therapeutic candidate with demonstrated bioactivity, manufacturability, biodistribution, in vivo efficacy, and/or target engagement (measurement of proximal downstream effects) and optimal dosing, combined with other properties consistent with the desired clinical application. This NOFO is not specific for any one or group within the ADRD spectrum of disorders. Disorders include; Frontotemporal dementia (FTD), Lewy body dementias (LBD) (including Dementia with Lewy bodies (DLB), Parkinson Disease Dementia (PDD)), Vascular contributions to Cognitive Impairment and Dementia (VCID), and Multiples Etiology Dementias (MED).

The purpose of this Notice of Funding Opportunity (NOFO) is toinvite applications that aggregate and analyze existing data in the COVID-19 Neuro Databank-Biobank (NeuroCOVIDProject).TheNeuroCOVIDProject was establishedin 2020 to serve as a robust national resource to understand theneurological complicationsassociated with COVID-19 and the effects of COVID-19 on pre-existing neurological conditions. The NeuroCOVID Project has collected and curated a wide range of data from the United States and international sites. This NOFO encourages hypothesis-driven applications to further scientific knowledge of neurological complications ofCOVID-19 by using this de-identified database. Thedata may be combined with data from other U.S. and International databases for analyses.However,collection of new primary data from those affected by COVID-19 or comparison cohorts isNOT covered by this NOFO.